drugset / Trial / NCT05328531
Clinical Study of Genakumab for Injection in Patients With Acute Gout
Phase 1/2
Completed
121 enrolled
Changchun GeneScience Pharmaceutical Co., Ltd.
Affiliated Hospital of Nantong University · collabChanghai Hospital · collabHainan General Hospital · collabHuashan Hospital · collabLinyi People's Hospital · collabShengjing Hospital · collabThe First Affiliated Hospital with Nanjing Medical University · collabThe Second Affiliated Hospital of Chongqing Medical University · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
To evaluate the safety and tolerability of single subcutaneous injection of Genakumab for Injection in patients with acute gout
Timeline
- Start
- 2021-05-22
- Primary completion
- 2022-06-09
- Completion
- 2022-06-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Genakumab | Monoclonal antibody | 50 mg | Subcutaneous |
| Subject | Genakumab | Monoclonal antibody | 100 mg | Subcutaneous |
| Subject | Genakumab | Monoclonal antibody | 195 mg | Subcutaneous |